Concepedia

Publication | Open Access

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

DOIFull Paper Access

136

Citations

12

References

2018

Year

Jennifer Mooi, Pratyaksha Wirapati, Rebecca Asher, Chee Khoon Lee, Peter Savas, Timothy Price, Amanda Townsend, Jennifer E. Hardingham, Daniel D. Buchanan, David S. Williams,
Annals of Oncology

Abstract

This is a molecular sub-study of MAX clinical trial (NCT00294359).

References

YearCitations

Page 1